Article

Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?

2021-08-16

Abstract excerpt

<h4>Background: </h4> The past two decades have witnessed significant growth in non-commercial research and development (R&D) initiatives, particularly for neglected diseases, but there is limited understanding of the ways in which they compare with commercial R&D. This study analyses costs, timelines, and attrition rates of non-commercial R&D across multiple initiatives and how they compare to commercial R&D. <h...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6dd74292-f941-5275-b241-66f21d2b61d1
DOI: 10.12688/f1000research.28281.2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?DOI 10.12688/f1000research.28281.2Read

Analysis of recurrent research pathways for assessing and improving effectiveness in life sciences laboratoriesSemantic proximity Read

Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global DisparitiesSemantic proximity Read

Design and rationale for an empirical investigation of the resource use and costs of investigator-initiated randomized trials in Switzerland, the United Kingdom, and GermanySemantic proximity Read

The Net Financial Benefits of Single Vendor Integrated CDMO and CRO Drug Development ServicesSemantic proximity Read

Financing translation: Analysis of the NCATS rare-diseases portfolioSemantic proximity Read

Financial Feasibility Study and policy recommendations of Incremental Modified Drugs Development by the Domestic Pharmaceutical IndustrySemantic proximity Read

Assessing the Value of Integrated Evidence Approaches in Drug DevelopmentSemantic proximity Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

To fully tackle the gang of four, needs-driven R & D is essential. Authors' reply [6].Semantic proximity Read

Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysisSemantic proximity Read

Cost of Goods Sold Analysis for Manufacturing mRNA-Based Cell and Gene TherapiesSemantic proximity Read

The Allocation of US$ 105 Billion in Global Funding for Infectious Disease Research between 2000 and 2017: An Analysis of Investments from Funders in the G20 CountriesSemantic proximity Read